Tirzepatide ���子背景与靶点 — Hands-On Walkthrough

By Editorial Desk · published 2025-09-17 · last reviewed 2025-10-27 · Guide

双受体激动 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-10-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。

Background and Molecular Development

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.

Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.

Tirzepatide at a glance

Background and Dual Receptor Pharmacology

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Related pages on this site

• Professional digest
• Comprehensive analysis
• Lightweight checklist
• Smart digest
• Material trends
• Simple analysis
• Balanced update
• Seasonal archive

Molecular Basis and Receptor Pharmacology

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

Dual Incretin Receptor Agonism

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Background And Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Notes from published material

Yessotoxins are a group of lipophilic, sulfur bearing polyether toxins that are related to ciguatoxins. They are produced by a variety of dinoflagellates, most notably Lingulodinium polyedrum and Gonyaulax spinifera. When the environmental conditions encourage the growth of YTX producing dinoflagellates, the toxin(s) bioaccumulate in edible tissues of bivalve molluscs, including mussels, scallops, and clams, thus allowing entry of YTX into the food chain.

An apparent attempt by a soldier in Baghdad to force a detainee to hold a gun to create the appearance of a justifiable homicide. Two mock executions of Iraqi juveniles by Army personnel (documents obtained by the ACLU two weeks ago showed that U.S. Marines had also conducted a mock execution of juvenile detainees). Allegations of a competition among Army dog handlers at Abu Ghraib prison to see who could make Iraqi detainees urinate themselves the fastest. The use of death threats during interrogations. Command failures in providing appropriate training to military interrogators in Baghdad detention facilities.

Carbamazepine is typically used for the treatment of seizure disorders and neuropathic pain. It is used off-label as a second-line treatment for bipolar disorder and in combination with an antipsychotic in some cases of schizophrenia when treatment with a conventional antipsychotic alone has failed. However, evidence does not support its usage for schizophrenia. It is not effective for absence seizures or myoclonic seizures. Although carbamazepine may have a similar effectiveness (as measured by people continuing to use a medication) and efficacy (as measured by the medicine reducing seizure recurrence and improving remission) when compared to phenytoin and valproate, it is not well-researched which medication is most helpful for people with newly-onset seizures. In the United States, carbamazepine is indicated for the treatment of epilepsy (including partial seizures, generalized tonic-clonic seizures and mixed seizures), and trigeminal neuralgia. Carbamazepine is the only medication that is approved by the Food and Drug Administration for the treatment of trigeminal neuralgia. As of 2014, a controlled release formulation was available for which there is tentative evidence showing fewer side effects and unclear evidence with regard to whether there is a difference in efficacy. In 2016, the FDA approved an intravenous formulation of carbamazepine, also granting it orphan drug status under the trade name Carnexiv, as a short-term replacement therapy for oral carbamazepine in adults with specific types of seizure disorders, who are unable to tolerate the oral formulation.

Sources: en.wikipedia.org

Background from the literature

==== Energy ==== The Lula government inaugurated, on 22 March, the first hybrid Renewable energy park in the country authorized by the National Electric Energy Agency (Aneel): the "Neo-energy Renewable Complex – Fountain Wind Farm", which consists of renewable Wind power and solar energy, located in Santa Luzia, Paraíba. In a meeting with the Minister of Mines and Energy, Alexandre Silveira, Lula showed support for the use of electricity derived from renewable sources, in particular for reducing the cost of the service, especially for the poor; goals were also discussed to place Brazil in a "leading global position in the generation of clean energy", in addition to encouraging more sustainable public transport.

Mifamurtide is muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic analogue of muramyl dipeptide. The side chains of the molecule give it a longer elimination half-life than the natural substance. The substance is applied encapsulated into liposomes (L-MTP-PE). Being a phospholipid, it accumulates in the lipid bilayer of the liposomes in the infusion.

== Sources cited == Emsley, John (2001). "Uranium". Nature's Building Blocks: An A to Z Guide to the Elements. Oxford, England: Oxford University Press. pp. 476–482. ISBN 978-0-19-850340-8. Seaborg, Glenn T. (1968). "Uranium". The Encyclopedia of the Chemical Elements. Skokie, Illinois: Reinhold Book Corporation. pp. 773–786. LCCN 68029938. Groves, Leslie R. (1962). Now It Can Be Told: The Story of the Manhattan Project. New York: Harper and Company. ISBN 0-306-80189-2. {{cite book}}: ISBN / Date incompatibility (help)

=== Other transplants and induced regeneration === There is ongoing research and development into synthetic biology based methods for inducing regeneration in humans as well the creation of transplantable artificial organs.

Sources: en.wikipedia.org

Reference notes

In November 1944, 3 Squadron RAAF became the first Royal Australian Air Force unit to use Mustangs. At the time of its conversion from the P-40 to the Mustang, the squadron was based in Italy with the RAF's Desert Air Force. 3 Squadron was renumbered 4 Squadron after returning to Australia from Italy, and converted to P-51Ds. Several other Australian or Pacific-based squadrons converted to either CAC-built Mustangs or to imported P-51Ks from July 1945, having been equipped with P-40s or Boomerangs for wartime service; these units were: 76, 77, 82, 83, 84 and 86 squadrons. Only 17 Mustangs reached the RAAF's First Tactical Air Force front-line squadrons by the time World War II ended in August 1945. 76, 77 and 82 squadrons were formed into 81 Fighter Wing of the British Commonwealth Air Force, which was part of the British Commonwealth Occupation Force stationed in Japan from February 1946. 77 Squadron used its P-51s extensively during the first months of the Korean War, before converting to Gloster Meteor jets. Five reserve units from the Citizen Air Force also operated Mustangs. 21 "City of Melbourne" Squadron, based in the state of Victoria; 22 "City of Sydney" Squadron, based in New South Wales; 23 "City of Brisbane" Squadron, based in Queensland; 24 "City of Adelaide" Squadron, based in South Australia; and 25 "City of Perth" Squadron, based in Western Australia; all of these units were equipped with CAC Mustangs, rather than P-51D or Ks. The last Mustangs were retired from these units in 1960 when CAF units adopted a nonflying role. Bolivia

Allyn Taylor International Prize in Medicine for Diabetes, Toronto, Canada (2002) Manpei Suzuki International Prize for Top Diabetes Researcher Worldwide (Inaugural Recipient), Tokyo, Japan (2009) Hans Falk Memorial Lecture, National Institute of Environmental Health Science (2009) Presidential Lecture, Memorial Sloan Kettering Cancer Institute, New York (2010) Alpha Omega Alpha Visiting Professor, Columbia University Medical School, New York, NY (2010) Frontiers in Science Award, American Association of Clinical Endocrinologists (2010) Cockrell Foundation Award in Basic and Clinical Research, Houston, TX (2010) Distinguished Leader in Insulin Resistance, World Congress of Insulin Resistance in Diabetes and Cardiovascular Disease, Los Angeles, CA (2010) David Murdock Dole Honorary Lecture, Mayo Clinic-Karolinska, Nobel Forum, Stockholm, Sweden (2011) Wallace H. Coulter Award, American Association of Clinical Chemistry (2013) Helmholtz Diabetes Research Lifetime Achievement Award, Munich, Germany (2013) Honorary Adjunct Member, Max Planck Institute, Cologne, Germany (2014) Ipsen Foundation Prize in Endocrine Regulation (2015) Harold Hamm Prize in Diabetes (2015) Wolf Prize in Medicine, Jerusalem, Israel (2016)

The NMR absorption frequency for tritium is also similar to that of 1H. In many other cases of non-radioactive nuclei, the overall spin is also non-zero and may have a contribution from the orbital angular momentum of the unpaired nucleon. For example, the 27Al nucleus has an overall spin value S = ⁠5/2⁠. A non-zero spin

Todd Lynn Helton (born August 20, 1973) is an American former professional baseball first baseman who played his entire 17-year Major League Baseball (MLB) career for the Colorado Rockies. A five-time All-Star, four-time Silver Slugger, and three-time Gold Glove Award winner, Helton holds the Rockies' club records for hits (2,519), home runs (369), doubles (592), walks (1,335), runs scored (1,401), runs batted in (RBIs, with 1,406), games played (2,247), and total bases (4,292), among others. Helton grew up in Tennessee and played college baseball and football for the Tennessee Volunteers. The Rockies drafted him in the first round of the 1995 MLB draft, and he debuted in the majors in 1997. During his peak from 1999 to 2004, Helton met or topped these benchmarks each season: .320 batting average, 39 doubles, 30 home runs, 107 runs scored, 96 RBI, .577 slugging percentage and .981 on-base plus slugging. In 2000, he won the batting title with a .372 average and also led MLB with a .698 slugging percentage, 59 doubles, and 147 RBI and the National League (NL) with 216 hits. Helton helped the Rockies win the NL pennant in 2007 before being swept in the World Series. He collected his 2,000th career hit in May 19, 2009 and his 2,500th on September 1, 2013. He retired at the end of that season, homering in his final game at Coors Field. Helton was inducted into the Baseball Hall of Fame in 2024, his sixth year on the ballot.

== Preparation, occurrence, and applications == Phenyl groups are usually introduced using reagents that behave as sources of the phenyl anion or the phenyl cation. Representative reagents include phenyllithium (C6H5Li) and phenylmagnesium bromide (C6H5MgBr). Electrophiles are attacked by benzene to give phenyl derivatives:

Sources: en.wikipedia.org

Frequently asked questions